Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-center Pharmacodynamics Study of TVB-2640 in KRAS Mutant Non-small Cell Lung Carcinomas

NCT03808558 is registered in ClinicalTrials.gov with David E Gerber as lead sponsor.

NCT NCT03808558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03808558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-center Pharmacodynamics Study of TVB-2640 in KRAS Mutant Non-small Cell Lung Carcinomas
Lead sponsor
David E Gerber
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 11, 2019
Completion date
December 1, 2026
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kras gene mutation